1. Lancet. 2015 May 16;385(9981):1957-65. doi: 10.1016/S0140-6736(14)61942-5.
Epub  2015 Jan 26.

Optimum and stepped care standardised antihypertensive treatment with or without 
renal denervation for resistant hypertension (DENERHTN): a multicentre, 
open-label, randomised controlled trial.

Azizi M(1), Sapoval M(2), Gosse P(3), Monge M(4), Bobrie G(4), Delsart P(5), 
Midulla M(6), Mounier-Véhier C(5), Courand PY(7), Lantelme P(8), Denolle T(9), 
Dourmap-Collas C(10), Trillaud H(11), Pereira H(12), Plouin PF(13), Chatellier 
G(14); Renal Denervation for Hypertension (DENERHTN) investigators.

Collaborators: Amar L, Bobrie G, Lorthioir A, Monge M, Pagny JY, Plouin PF, 
Sapoval M, Claisse G, Delsart P, Midulla M, Mounier-Vehier C, Herriot E, Courand 
PY, Dauphin R, Fauvel JP, Lantelme P, Rouvière O, Cremer A, Gosse P, Grenier N, 
Lebras Y, Trillaud H, Denolle T, Dourmap-Collas C, Heautot JF, Larralde A, 
Paillard F, Cluzel P, Girerd X, Rosenbaum D, Alison D, Halimi JM, Claudon M, 
Popovic B, Rossignol P, Zannad F, Baguet JP, Ormezzano O, Thony F, Bartoli JM, 
Vaïsse B, Drouineau J, Herpin D, Sosner P, Tasu JP, Velasco S, Ribstein J, 
Vernhet-Kovacsik H, Duly-Bouhanick B, Chamontin B, Rousseau H, Le Jeune S, 
Lopez-Sublet M, Mourad JJ, Bellmann L, Esnault V, Ferrari E, Azizi M, Sapoval M, 
Bobrie G, Chatellier G, Plouin PF, Zannad F, Halimi JM, Baguet JP, 
Vernhet-Kovacsik H, Durand-Zaleski I, Beregi JP, Lièvre M, Persu A.

Author information:
(1)Paris-Descartes University, Paris, France; Hypertension Unit, Assistance 
Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France; 
Institut National de la Santé et de la Recherche Médicale (INSERM), Centre 
d'Investigations Cliniques 1418, Paris, France. Electronic address: 
michel.azizi@egp.aphp.fr.
(2)Paris-Descartes University, Paris, France; Vascular and Oncological 
Interventional Radiology Department, Assistance Publique-Hôpitaux de Paris, 
Hôpital Européen Georges Pompidou, Paris, France.
(3)Cardiology/Hypertension Department, Centre Hospitalier Universitaire de 
Bordeaux Hôpital Saint André, Bordeaux, France.
(4)Hypertension Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Européen 
Georges Pompidou, Paris, France.
(5)Centre Hospitalier Régional Universitaire de Lille, Hôpital Cardiologique, 
Médecine Vasculaire et HTA Lille, France.
(6)Centre Hospitalier Régional Universitaire de Lille, Hôpital Cardiologique, 
Radiologie et Imagerie Cardiaque et Vasculaire, Lille, France.
(7)Hôpital Croix-Rousse, Cardiology Department, European Society of Hypertension 
Excellence Centre, Hospices Civils de Lyon, Lyon, France.
(8)Hôpital Croix-Rousse, Cardiology Department, European Society of Hypertension 
Excellence Centre, Hospices Civils de Lyon, Lyon, France; Génomique 
Fonctionnelle de l'Hypertension Artérielle, Université Claude Bernard Lyon 1, 
Villeurbanne, France.
(9)Hôpital Arthur Gardiner, Centre d'Excellence en HTA Rennes-Dinard, Dinard, 
France.
(10)Centre Hospitalier Universitaire de Rennes, Service de Cardiologie et 
Maladies Vasculaires, Rennes, France.
(11)Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint André, Service 
d'Imagerie Diagnostique et Interventionnelle, Bordeaux, France.
(12)Institut National de la Santé et de la Recherche Médicale (INSERM), Centre 
d'Investigations Cliniques 1418, Paris, France.
(13)Paris-Descartes University, Paris, France; Hypertension Unit, Assistance 
Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
(14)Paris-Descartes University, Paris, France; Institut National de la Santé et 
de la Recherche Médicale (INSERM), Centre d'Investigations Cliniques 1418, 
Paris, France.

Comment in
    Lancet. 2015 May 16;385(9981):1922-4.
    Nat Rev Nephrol. 2015 May;11(5):258-60.
    Lancet. 2015 Sep 26;386(10000):1239-40.
    Lancet. 2015 Sep 26;386(10000):1240.

BACKGROUND: Conflicting blood pressure-lowering effects of catheter-based renal 
artery denervation have been reported in patients with resistant hypertension. 
We compared the ambulatory blood pressure-lowering efficacy and safety of 
radiofrequency-based renal denervation added to a standardised stepped-care 
antihypertensive treatment (SSAHT) with the same SSAHT alone in patients with 
resistant hypertension.
METHODS: The Renal Denervation for Hypertension (DENERHTN) trial was a 
prospective, open-label randomised controlled trial with blinded endpoint 
evaluation in patients with resistant hypertension, done in 15 French tertiary 
care centres specialised in hypertension management. Eligible patients aged 
18-75 years received indapamide 1·5 mg, ramipril 10 mg (or irbesartan 300 mg), 
and amlodipine 10 mg daily for 4 weeks to confirm treatment resistance by 
ambulatory blood pressure monitoring before randomisation. Patients were then 
randomly assigned (1:1) to receive either renal denervation plus an SSAHT 
regimen (renal denervation group) or the same SSAHT alone (control group). The 
randomisation sequence was generated by computer, and stratified by centres. For 
SSAHT, after randomisation, spironolactone 25 mg per day, bisoprolol 10 mg per 
day, prazosin 5 mg per day, and rilmenidine 1 mg per day were sequentially added 
from months two to five in both groups if home blood pressure was more than or 
equal to 135/85 mm Hg. The primary endpoint was the mean change in daytime 
systolic blood pressure from baseline to 6 months as assessed by ambulatory 
blood pressure monitoring. The primary endpoint was analysed blindly. The safety 
outcomes were the incidence of acute adverse events of the renal denervation 
procedure and the change in estimated glomerular filtration rate from baseline 
to 6 months. This trial is registered with ClinicalTrials.gov, number 
NCT01570777.
FINDINGS: Between May 22, 2012, and Oct 14, 2013, 1416 patients were screened 
for eligibility, 106 of those were randomly assigned to treatment (53 patients 
in each group, intention-to-treat population) and 101 analysed because of 
patients with missing endpoints (48 in the renal denervation group, 53 in the 
control group, modified intention-to-treat population). The mean change in 
daytime ambulatory systolic blood pressure at 6 months was -15·8 mm Hg (95% CI 
-19·7 to -11·9) in the renal denervation group and -9·9 mm Hg (-13·6 to -6·2) in 
the group receiving SSAHT alone, a baseline-adjusted difference of -5·9 mm Hg 
(-11·3 to -0·5; p=0·0329). The number of antihypertensive drugs and 
drug-adherence at 6 months were similar between the two groups. Three minor 
renal denervation-related adverse events were noted (lumbar pain in two patients 
and mild groin haematoma in one patient). A mild and similar decrease in 
estimated glomerular filtration rate from baseline to 6 months was observed in 
both groups.
INTERPRETATION: In patients with well defined resistant hypertension, renal 
denervation plus an SSAHT decreases ambulatory blood pressure more than the same 
SSAHT alone at 6 months. This additional blood pressure lowering effect may 
contribute to a reduction in cardiovascular morbidity if maintained in the long 
term after renal denervation.
FUNDING: French Ministry of Health.

Copyright © 2015 Elsevier Ltd. All rights reserved.

DOI: 10.1016/S0140-6736(14)61942-5
PMID: 25631070 [Indexed for MEDLINE]
